Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2024-01-04 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks for Ascletis Pharma Inc. It includes detailed information on repurchases of shares, dates, quantities, prices, and confirmations of compliance with listing rules on the Stock Exchange of Hong Kong. The content focuses on share repurchase activities and changes in share capital rather than financial results, management commentary, or regulatory certifications. This matches the description of a 'Transaction in Own Shares' filing, which reports the company's buyback or sale of its own shares. The document length is substantial and contains detailed transactional data, not merely an announcement or certification, so it is not a Regulatory Filing or Report Publication Announcement. Therefore, the appropriate classification is 'POS' (Transaction in Own Shares).
2024-01-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
Transaction in Own Shares Classification · 95% confidence The document is a detailed monthly report on movements in securities for Ascletis Pharma Inc., including authorized share capital, issued shares, share options, and share repurchases. It is addressed to the Hong Kong Exchanges and Clearing Limited and follows a standard form (FF301) used for reporting share capital and share movements under the Exchange Listing Rules. The content focuses on share capital changes, share options, and repurchases, with no financial statements or earnings data. This type of document is a regulatory filing related to share capital movements and share repurchases but does not constitute a financial report or earnings release. It is not an announcement of a report publication but a substantive regulatory disclosure. The closest fitting category is Transaction in Own Shares (POS), as it reports on share repurchases and movements in issued shares.
2024-01-04 English
GRANT OF SHARE OPTIONS
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the grant of share options to directors and employees of Ascletis Pharma Inc. It details the number of options granted, exercise price, vesting period, and other terms related to the share option scheme. The document references compliance with the Listing Rules of the Hong Kong Stock Exchange and includes information about the board's approval and the number of shares available for future grants. There is no financial report, earnings data, or management discussion of financial results. The content is focused on the issuance of share options, which is a capital-related update. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a regulatory filing fallback. Confidence is high due to clear and specific content about share option grants.
2024-01-03 English
VOLUNTARY ANNOUNCEMENT - GANNEX ANNOUNCES POSITIVE INTERIM RESULTS FROM 52-WEEK PHASE II CLINICAL TRIAL OF ONCE-DAILY ASC41 TABLET IN PATIENTS WITH BIOPSY-CONFIRMED NON-ALCOHOLIC STEATOHEPATITIS
Interim / Quarterly Report Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding positive interim results from a 52-week Phase II clinical trial of a drug candidate ASC41 tablet. It contains detailed clinical trial data, including statistical results, safety and tolerability information, and study design specifics. The document is not a full annual or quarterly financial report, nor is it an earnings release or regulatory filing. It is a clinical trial interim result announcement, which is a type of business development update. Given the detailed interim data and the nature of the announcement, it fits best under the category of Interim / Quarterly Report (IR), as it provides substantive interim results and analysis for a period shorter than a full fiscal year. The document length (over 10,000 characters) and detailed data support this classification rather than a brief announcement or regulatory filing. FY 2023
2024-01-02 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 December 2023
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return concerning movements in securities for a Hong Kong listed company, including authorized share capital, issued shares, share options, and confirmations related to securities issuance. It is addressed to the Hong Kong Exchanges and Clearing Limited and references specific listing rules (Chapter 19B, Main Board Rule 13.25A / GEM Rule 17.27A). The content focuses on share capital changes and confirmations of compliance with listing requirements, typical of regulatory filings related to share capital movements. It does not contain financial statements, earnings data, or management discussion, nor is it an announcement of a report publication. The document is a regulatory compliance filing reporting share capital and securities movements for the month ended 31 December 2023. Therefore, it fits best under Regulatory Filings (RNS).
2024-01-02 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and pertains to changes in issued share capital and share buybacks for Ascletis Pharma Inc. It includes detailed tables of repurchase of shares with dates and quantities, referencing compliance with listing rules of the Stock Exchange of Hong Kong. The content is a regulatory disclosure about share repurchases, not a financial report, earnings release, or management discussion. It is a formal notification of transactions in the company's own shares (share buybacks). Therefore, the document fits the category of 'Transaction in Own Shares' (POS). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive disclosure of share repurchase activity.
2023-12-22 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.